Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E50.41 EPS (ttm)2.66 Insider Own0.20% Shs Outstand779.00M Perf Week6.94%
Market Cap104.27B Forward P/E15.22 EPS next Y8.80 Insider Trans33.41% Shs Float778.91M Perf Month14.66%
Income2.14B PEG2.43 EPS next Q1.78 Inst Own80.10% Short Float1.22% Perf Quarter7.20%
Sales11.68B P/S8.93 EPS this Y28.10% Inst Trans0.65% Short Ratio2.49 Perf Half Y13.56%
Book/sh9.81 P/B13.64 EPS next Y20.74% ROA7.80% Target Price142.04 Perf Year39.01%
Cash/sh11.37 P/C11.77 EPS next 5Y20.71% ROE33.60% 52W Range94.42 - 135.18 Perf YTD15.64%
Dividend- P/FCF38.97 EPS past 5Y11.80% ROI11.70% 52W High-0.98% Beta1.92
Dividend %- Quick Ratio4.20 Sales past 5Y18.30% Gross Margin96.20% 52W Low41.76% ATR2.54
Employees7132 Current Ratio4.40 Sales Q/Q17.90% Oper. Margin24.80% RSI (14)78.71 Volatility2.83% 2.01%
OptionableYes Debt/Eq1.87 EPS Q/Q17.00% Profit Margin18.30% Rel Volume1.02 Prev Close134.31
ShortableYes LT Debt/Eq1.80 EarningsJul 27 BMO Payout0.00% Avg Volume3.80M Price133.85
Recom1.80 SMA2010.42% SMA5010.44% SMA20014.83% Volume3,882,965 Change-0.34%
Jun-16-17Upgrade Leerink Partners Mkt Perform → Outperform
Jun-01-17Reiterated Mizuho Buy $130 → $134
May-05-17Downgrade Argus Buy → Hold
Mar-09-17Initiated UBS Buy $140
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Nov-06-15Reiterated UBS Buy $156 → $145
Oct-01-15Upgrade JP Morgan Neutral → Overweight
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $160
Jul-24-15Reiterated UBS Buy $142 → $156
Jul-24-15Reiterated JMP Securities Mkt Outperform $133 → $147
Jul-24-15Reiterated Cantor Fitzgerald Buy $146 → $163
Jun-26-17 04:17PM  Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone Investor's Business Daily
02:52PM  Seattle Genetics: A Disappointing StudyOr Was It? Barrons.com
11:05AM  Agio Pharma Sinks on Midstage Trial 24/7 Wall St.
08:43AM  Corcept Therapeutics Incorporated in 3 Charts Motley Fool
Jun-25-17 11:01AM  3 Reasons to Buy Celgene Stock and Never Sell Motley Fool
Jun-24-17 08:33AM  2 Top Biotech Stocks to Buy on Sale Motley Fool
Jun-23-17 09:00PM  On Not Talking About the 'Market'; Darth Vader, Meet Amazon: Jim Cramer's Best Blog TheStreet.com
04:36PM  Week In Review: Biotechs, Software Drive Nasdaq; Boeing Tops Airbus; Oil Hit Investor's Business Daily
08:04AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jun-22-17 04:50PM  Biotech Resurgence Has Bite But No FAANGs Forbes
04:30PM  This Top Biotech Stock Remains Just Within Buy Range Investor's Business Daily
04:27PM  After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Investor's Business Daily
04:05PM  Why The Biotech Rally Could Still Tack On Another 15% Upside Investor's Business Daily
02:47PM  Which Stocks Are Showing Rising Relative Strength? Investor's Business Daily
12:11PM  Stock Indexes Grip Small Gains, But This New Leader Swings Higher Investor's Business Daily
09:06AM  Otezla Could Significantly Drive Celgenes Revenue Growth Market Realist
09:00AM  Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgenes SHOW MORE OF YOU Campaign Business Wire
07:36AM  What Analysts Recommend for Celgene in 2017 Market Realist
06:48AM  Futures: These 2 Big Breakouts Highlight New Market Leadership Investor's Business Daily
Jun-21-17 08:21PM  Celgene Is Headed Much Higher Even After a Monster Breakout TheStreet.com +5.24%
06:00PM  Cramer finds where the real growth is in a split market CNBC Videos
05:48PM  Finding real growth in a split market CNBC Videos
05:08PM  Technician: Forget tech, keep buying health-care stocks CNBC Videos
04:11PM  Biotech Breakouts: Biogen Spinoff Bioverativ In Buy Zone Investor's Business Daily
04:08PM  Benzinga's Option Alert Recap From June 21 Benzinga
03:48PM  When 'New' Means A Stock Hasn't Led The Market In A While Investor's Business Daily
03:45PM  Nasdaq Leads Again; Are These 3 Stocks The Next Apple In Biotech Land? Investor's Business Daily
12:03PM  Nasdaq Rises; Is Celgene Back From A Two-Year Slump? Investor's Business Daily
10:38AM  An Overview of Celgenes Hematology and Oncology Pipeline Market Realist
10:35AM  Amgen: In Defense of A Pipeline Barrons.com
09:08AM  Whats in Celgenes Immunology and Inflammation Clinical Pipeline? Market Realist
07:37AM  Why Abraxane Could See Steady Growth in 2017 Market Realist
Jun-20-17 06:05PM  Why Pomalyst Could See Significant Revenue Growth in 2017 Market Realist
05:35PM  Traders favorite Nvidia should be a long-term investors favorite too, strategist argues CNBC
04:36PM  Revlimid Could Continue to Drive Celgenes Revenue Growth in 2017 Market Realist
04:27PM  Which Companies Are Now Outperforming 95% Of All Stocks? Investor's Business Daily
04:13PM  Biotech Stock With 50% Profit Margin Nears Buy Zone Investor's Business Daily
03:05PM  Nasdaq Falls, Dow Holds Up; Biotechs On Fire As Oil Slumps Again Investor's Business Daily
02:45PM  How Did Celgene Perform in 1Q17? Market Realist
02:39PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
11:01AM  Biotech Funds Could Break Out Investopedia
09:06AM  Analyzing Eli Lillys Collaboration with KeyBioscience AG Market Realist
Jun-19-17 11:11AM  Biogen: "The Underperformance Stops Here" Barrons.com
11:01AM  Celgene Presents Interim Results from Cancer Drug Study Zacks
09:30AM  The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Celgene, PayPal and Southern Zacks
08:43AM  J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use Zacks
07:30AM  Celgene Announces Clinical Data Evaluating Broad Range of Blood Cancers to Be Presented at EHA 2017 Business Wire
Jun-18-17 09:07AM  3 Top Healthcare Stocks You Haven't Thought Of Motley Fool
Jun-17-17 07:30AM  Updated Data from Phase IIIb MAGNIFY Study of REVLIMID (lenalidomide) and Rituximab Combination (R2) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma Business Wire
Jun-16-17 04:47PM  Celgene's Future Is Tied To One 'Mixer' Drug And That's OK Investor's Business Daily
04:42PM  Celgene Corp. Value Analysis (NASDAQ:CELG) : June 16, 2017 Capital Cube
04:06PM  Nike, Kroger Downgraded; Celgene Upgraded; Lam Research Gets PT Hike Investor's Business Daily
02:50PM  Why Celgene is Bucking Biotech Weakness Today Barrons.com
01:08PM  Top Analyst Reports for Apple, Procter & Gamble, and Celgene Zacks
12:47PM  2 Incredibly Cheap Biotech Stocks Motley Fool
08:30AM  Morning Movers: Celgene Gains, Nike Drops, Valeant Rises Barrons.com
07:41AM  3 Top-Performing Biotech Stocks This Week Motley Fool
Jun-15-17 05:45PM  Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial Zacks
03:20PM  Could This Small Biotech Pique Interest Of Gilead And Others? Investor's Business Daily
09:11AM  Can Celgene Corporation Be a Value Stock? Motley Fool
08:26AM  Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug Zacks
08:14AM  Celgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : June 15, 2017 Capital Cube
Jun-14-17 07:30AM  Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus Business Wire
Jun-13-17 09:29AM  Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool
08:00AM  Today's Research Reports on Stocks to Watch: Celgene and Teva Pharmaceutical Industries Accesswire
07:24AM  Celgene's Next Blockbuster: What You Need to Know Motley Fool
Jun-12-17 05:51PM  [$$] Dragonfly Therapeutics Strikes Immuno-Oncology Deal With Celgene The Wall Street Journal
05:18PM  Merck to pause two late-stage studies testing Keytruda in myeloma Reuters
11:15AM  Waltham-based Dragonfly inks collaboration with Celgene, bags $33M American City Business Journals
10:47AM  Moody's: Patent invalidation creates risk for US branded drug makers Moody's
09:40AM  Short Interest Surges in Major Biotechs 24/7 Wall St.
08:23AM  9 Biotech Stats That Will Blow You Away Motley Fool
Jun-09-17 12:17PM  The 3 Best Value Stocks You Can Buy Right Now Motley Fool
11:07AM  Celgene Corporation (CELG) Stocks Range Is Tight Time to Profit InvestorPlace
07:22AM  2 Reasons Why Biogen's Shares Slumped in May Motley Fool
Jun-08-17 10:13AM  Juno Therapeutics: To Sell, Or Not To SellGood Question Barrons.com
09:44AM  3 Large-Cap Stocks for June Motley Fool
Jun-07-17 04:53PM  Why bluebird bio Inc. Flew Higher Again Today Motley Fool
12:56PM  ASCO Was A Bust For Biotech Barrons.com
10:07AM  Celgene and Agios Announce Data on Idhifa for Leukemia Zacks
08:22AM  3 Promising Stocks to Buy Now Motley Fool
Jun-06-17 04:58PM  This Small Biotech Soared On Its Celgene-Partnered Trial Investor's Business Daily
04:34PM  3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene Benzinga
03:43PM  Top Health Stocks to Buy Now Motley Fool
01:40PM  Why bluebird bio Inc Flew Higher Today Motley Fool
12:26PM  Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation Business Wire
09:14AM  Why Halozyme Therapeutics Inc. Sank 16.5% in May Motley Fool
06:30AM  Bluebird and Radius gain, while Blueprint and Tesaro fall, at ASCO cancer summit American City Business Journals
Jun-05-17 05:28PM  Bluebird Bio shares pop on what CEO calls very exciting cancer news CNBC
01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga
09:46AM  UPDATE: Bluebird Bio stock rises 7.4% on positive data from ongoing early-stage clinical trial MarketWatch
09:34AM  Bluebird Bio stock rises 5% on positive data from ongoing early-stage clinical trial MarketWatch
08:34AM  Celgene CEO on paying for cancer care CNBC Videos
07:30AM  Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free TheStreet.com
07:30AM  bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Business Wire
Jun-04-17 11:41AM  3 Biotech Stocks to Buy If You've Never Bought a Biotech Stock Motley Fool
Jun-02-17 11:52AM  Celgene & Acceleron Complete Enrollment on Thalassemia Drug Zacks
Jun-01-17 07:30AM  Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia Business Wire
06:05AM  Top 3 Healthcare Stocks for 2017 Investopedia
May-31-17 08:06AM  Celgene's Stock May Be Incredibly Overvalued Right Now -- Here's Why Motley Fool
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM
CASEY MICHAEL DDirectorOct 18Option Exercise100.067,500750,45092,985Oct 19 04:16 PM
Friedman Michael ADirectorOct 03Option Exercise29.8656,1161,675,36456,116Oct 05 04:09 PM
Friedman Michael ADirectorOct 03Sale103.6656,1165,816,9850Oct 05 04:09 PM
BARKER RICHARD WDirectorSep 23Option Exercise36.9220,000738,40031,332Sep 26 04:08 PM
BARKER RICHARD WDirectorSep 23Sale110.8220,0002,216,40011,332Sep 26 04:08 PM
MARIO ERNESTDirectorSep 23Sale109.4215,0001,641,30090,058Sep 26 04:08 PM
KAPLAN GILLADirectorSep 19Option Exercise29.267,500219,45079,642Sep 20 04:42 PM
KAPLAN GILLADirectorSep 15Sale106.449,7101,033,53272,142Sep 16 04:15 PM
LOUGHLIN JAMES JDirectorAug 23Option Exercise26.3627,500724,85050,419Aug 24 04:28 PM
LOUGHLIN JAMES JDirectorAug 23Sale114.1027,5003,137,75022,919Aug 24 04:28 PM
CASEY MICHAEL DDirectorAug 22Sale114.0143,1344,917,70785,485Aug 23 04:29 PM
HUGIN ROBERT Jsee remarksJul 28Sale110.00100,00011,000,0001,022,201Aug 01 05:04 PM
MARIO ERNESTDirectorJul 01Option Exercise0.007330105,058Jul 05 04:32 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00733022,919Jul 05 04:30 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073300Jul 05 04:27 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00733081,852Jul 05 04:28 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00733023,146Jul 05 04:27 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00733011,551Jul 05 04:25 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073300Jul 05 04:26 PM